普罗布考对急性期缺血性卒中患者血清MMP-9抑制作用的相关研究

Inhibition Effect of Probucol on the Level of MMP-9 in Acute Stage of Cerebral Infarction

目的探讨普罗布考对缺血性卒中患者急性期血清基质金属蛋白酶-9（matrix metalloproteinases-9,MMP-9）水平的影响。方法采用自身对照和组间对照,随机将82例急性期缺血性卒中患者分为两组：普罗布考组（42例）和常规治疗组（40例）,采用酶联免疫吸附双抗夹心测定法分别测定治疗前后血清MMP-9水平的变化。结果（1）普罗布考组治疗前血清MMP-9水平为399±85ng/ml,治疗两周后血清MMP-9水平为174±56ng/ml,较治疗前明显降低（P〈0.05）;而常规治疗组治疗前血清MMP-9水平为401±62ng/ml,治疗两周后血清MMP-9水平为353±90ng/ml,治疗前后无统计学差异（P〉0.05）;（2）治疗两周后普罗布考组血清MMP-9水平较常规治疗组明显降低（P〈0.05）。结论普罗布考能降低急性期缺血性卒中患者血清MMP-9水平,从而减轻缺血性脑损伤,防止缺血性卒中出血转化和再发。

Objective To observe the effect of probucol on the level of MMP-9 in acute stage of cerebral infarction. Methods Using a random and single blind control test ,82 patients with cerebral infarction in acute stage were randomed into probucol group （n=42） and control group （n=40）. With the method of ELISA, the levels of MMP-9in serum were measured before and after therapy. Results （1） The serum MMP-9 levels of Probucol group pre-treatment was 398.67±84.92ng/ml, two weeks after treatment 173.80±55.68ng/ml, significantly lower than that before treatment （P〈0.05）; The serum MMP-9 levels of control group pre-treatment serum levels was 401.12±62.56ng/ml, two weeks after treatment 352.98±89.65ng/ml, no significant difference between before and after treatment （P〉0.05）; （2） At the end of two weeks after treatment, the serum MMP-91evels of robucol group was significantly lower than that of control group （P〈0.05）. Conclusion Probucol can reduce the level of MMP-9 in acute stage of cerebra linfarction, thus may relieve the ischemic brain injury.